What's Hot
View all perspectives
Dr. Rachel Tate uptoTate
2 years 5 months ago
SpA pregnancies in #EULAR2022 POS1051 found that 40% of pts flared, particularly during their 2nd trimester in those with axial involvement OR post-partum. Seven flares led to TNFi initiation in 2nd or 3rd trimesters and were without correlation in post-partum flares. @RheumNow https://t.co/0ZWjYMwmzn
Richard Conway RichardPAConway
2 years 5 months ago
Dr Patel @NaomiRheumMD et al. Avacopan in AAV at different thresholds toxicity. Minimum clinically important difference for GTI is 10 points. Avacopan assoc lower glucocorticoid toxicity irrespective of threshold used. @RheumNow #EULAR2022 POS0833 https://t.co/8iIIAsMOlI
Richard Conway RichardPAConway
2 years 5 months ago
Brevet et al. SAPHO syndrome. Divided into bone group and joint/mixed group. Better response to bisphosphonate in bone group 60% vs 6%. Better response to DMARD in joint/mixed group 94% vs 40% @RheumNow #EULAR2022 POS1333 https://t.co/FfYBIEGGgJ
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 POS0207
Fatigue in early RA:
⭐️Does not show direct effect between inflammation on fatigue
⭐️Suggests broader indirect effect of psychosocial aspects of wellbeing (pain, mental health, sleep, disease perception) plays larger role
@Rheumnow https://t.co/zTxk7kZRIX
Richard Conway RichardPAConway
2 years 5 months ago
Szekanecz et al. ORAL Surveillance. Geographic differences in MACE largely driven by history CVD and high baseline risk in North America and ROW. @RheumNow #EULAR2022 POS0110 https://t.co/cR6a7N2KP5
Richard Conway RichardPAConway
2 years 5 months ago
Unizony et al. GCA outcome on/after tocilizumab. 36.5% relapse after stopping tocilizumab. Generally stopped due to remission, 10% stopped due to adverse event @RheumNow #EULAR2022 POS0267 https://t.co/jlZDTinfCK
Dr. Antoni Chan synovialjoints
2 years 5 months ago
The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
David Liew drdavidliew
2 years 5 months ago
For psoriasis +MSK pain, should we be chasing synovitis/enthesitis on ultrasound?
PsO pts with MSK pain n=79
USS inflamm in 47%
Site-spec correlate only OR 3.1
Even if we act on USS:
PsA Rx is systemic, so overall impression is good enough anyway?
POS0131 #EULAR2022 @RheumNow https://t.co/O3P7J2Rskw
Robert B Chao, MD doctorRBC
2 years 5 months ago
Are wearable devices useful in assessing physical activity in rheumatic diseases?
Meta-analysis showed pts with rheumatic diseases reached recommended threshold for moderate to vigorous physical activity but not daily steps.
@RheumNow #EULAR2022 POST#POS0163
Richard Conway RichardPAConway
2 years 5 months ago
Schmitt et al. Pharmacokinetic study of IV tocilizumab in 24 patients with known GCA. Using 6mg/kg or 7mg/kg. Effective on lab measures and no GCA flares. @RheumNow #EULAR2022 POS0268 https://t.co/uhxfGZvYTw
TheDaoIndex KDAO2011
2 years 5 months ago
OP0283 MMF vs CYP for induction of remission #LupusNephritis. Real world Beijing cohort. n=360 50% Rx naïve. CRR at 1 yr was more common in MMF, esp proliferative LN. GI & infection more common w/CYP. Lower prednisone dose and Urinary protein seen in MMF #EULAR2022 @rheumnow https://t.co/4P43j1rApF
Richard Conway RichardPAConway
2 years 5 months ago
Dougados et al. MACE in tofa clinical programme. Baseline CV risk important. Overall MACE IR 0.38 [0.26-0.54]. MACE IR lower than in ORAL Surveillance in CV enriched pop 0.72 [0.46-1.09]. @RheumNow #EULAR2022 OP0264 https://t.co/lGTTEx0X5p https://t.co/MvD6kjkpse
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 POS0210
RNA sequencing in 11 RA-ILD patients vs 9 RA pts
⭐️Distinct gene expression in RA-ILD with type 1 IFN response, neutrophil activation, and degranulation and CCR1 chemokine interactions
@RheumNow
@fahidalghanim https://t.co/FIrZfzZV1C
Poster Hall